The basis for the IMF “Beyond Medicine’s Barriers” meeting is to leverage patients, patient advocates, researchers, health care professionals, health economists, societal representatives, myeloma experts, and pharmaceutical companies, and discuss and initiate ways to optimize the use of new medicines – balancing rising costs with increasing budgetary pressures and stimulating access to medicines.

The IMF is the first and largest global organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure of the disease.

“For Nanexa as a small pharmaceutical company with clinical development of a new medicine against multiple myeloma, it is very important to have the opportunity to participate at an international meeting of this kind. It is a good venue for us to discuss the question around the compliance and adherence to the medications that myeloma patients are treated with for their disease”, says Bengt Gustavsson, Director Clinical Development and Medical Affairs at Nanexa.